Clinical Report: Management of Brain Metastases in the Era of Novel Systemic Therapies

Overview

This retrospective cohort study of 676 patients with brain metastases (BM) treated at a single tertiary cancer center evaluates the integration of systemic therapies with radiotherapy. It highlights the complexity of treatment decisions influenced by tumor type, systemic treatment status, and multidisciplinary board recommendations, emphasizing the evolving role of systemic treatments alongside local therapies.

Background

Brain metastases are a common complication in advanced cancer, with treatment historically focused on local modalities such as radiotherapy. The advent of targeted molecular therapies and immunotherapies has improved control of extracranial metastases, raising questions about their efficacy and role in managing intracranial disease. Response to systemic treatments in the brain varies widely depending on tumor biology and molecular drivers, necessitating careful patient selection. Multidisciplinary approaches and predictive models guide treatment decisions, but individualized management remains challenging.

Data Highlights

Key Findings

• Systemic treatment status at BM diagnosis was categorized into five groups: first systemic treatment, continued, switched, no treatment but options available, and no options.
• Patients were triaged into three groups based on multidisciplinary board decisions: immediate radiotherapy, awaiting systemic treatment response with possible salvage radiotherapy, and best supportive care without local treatment.
• Radiotherapy modalities included single fraction, fractionated, staged stereotactic radiotherapy, postoperative cavity SRT, and whole brain radiotherapy.
• Overall survival was assessed from BM diagnosis, with treatment decisions influenced by clinical parameters such as Karnofsky Performance Score, extracranial metastases status, and primary tumor type.
• Systemic therapies targeted specific mutations (ALK, EGFR, PD-L1 in NSCLC; BRAF in melanoma), reflecting personalized treatment approaches.

Clinical Implications

The study underscores the importance of a multidisciplinary approach in managing brain metastases, integrating systemic therapies with local radiotherapy tailored to individual patient and tumor characteristics. Understanding systemic treatment status and molecular drivers can guide timing and modality of radiotherapy, potentially improving outcomes. Clinicians should consider systemic treatment response when planning local therapies and maintain flexibility to adapt treatment strategies based on intracranial disease dynamics.

Conclusion

Incorporating novel systemic therapies into the management of brain metastases requires nuanced clinical decision-making supported by multidisciplinary collaboration. This real-world data highlights the evolving landscape where systemic and local treatments are combined to optimize patient outcomes.

References

1. Various Authors/Studies 2018-2023 -- Enhancing Management of Brain Metastases Amidst Emerging Systemic Therapies